Neurocrine Biosciences Inc
NASDAQ:NBIX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
87.54
155.63
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
NBIX
stock under the Base Case scenario is
150.55
USD.
Compared to the current market price of 145.26 USD,
Neurocrine Biosciences Inc
is
Undervalued by 4%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Neurocrine Biosciences Inc.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Neurocrine Biosciences’ heavy reliance on Ingrezza for the bulk of its revenue leaves the company vulnerable should sales or market share of this core product decline, exposing a significant revenue concentration risk.
Patent expiration and looming generic entrants in the tardive dyskinesia space could erode Neurocrine’s pricing power, pressuring margins and diminishing its competitive edge.
Uncertainty around promising pipeline candidates, including potential delays or failures in late-stage clinical trials, could limit future growth opportunities and lead to increased R&D spend without near-term returns.
Ingrezza continues to show strong sales momentum, fueled by expanding market penetration for tardive dyskinesia and steady physician adoption, supporting robust cash flows.
A well-funded R&D platform and a growing pipeline in movement disorders and other neurological conditions position Neurocrine for long-term growth if even a few candidates reach commercialization.
Partnerships with prominent pharmaceutical players, such as AbbVie, and recent collaborations for new programs help diversify Neurocrine’s development efforts, reduce risk, and expand its addressable markets.
Revenue & Expenses Breakdown
Neurocrine Biosciences Inc
Balance Sheet Decomposition
Neurocrine Biosciences Inc
| Current Assets | 2.2B |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 728m |
| Other Current Assets | 315.6m |
| Non-Current Assets | 2.1B |
| Long-Term Investments | 1.1B |
| PP&E | 566.2m |
| Intangibles | 35.7m |
| Other Non-Current Assets | 388.8m |
| Current Liabilities | 638m |
| Accounts Payable | 396.8m |
| Accrued Liabilities | 238.8m |
| Other Current Liabilities | 2.4m |
| Non-Current Liabilities | 624.1m |
| Other Non-Current Liabilities | 624.1m |
Free Cash Flow Analysis
Neurocrine Biosciences Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Neurocrine Biosciences Inc
|
Revenue
|
2.7B
USD
|
|
Cost of Revenue
|
-43.8m
USD
|
|
Gross Profit
|
2.6B
USD
|
|
Operating Expenses
|
-2.1B
USD
|
|
Operating Income
|
553.6m
USD
|
|
Other Expenses
|
-125.6m
USD
|
|
Net Income
|
428m
USD
|
NBIX Profitability Score
Profitability Due Diligence
Neurocrine Biosciences Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Neurocrine Biosciences Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
NBIX Solvency Score
Solvency Due Diligence
Neurocrine Biosciences Inc's solvency score is 90/100. The higher the solvency score, the more solvent the company is.
Score
Neurocrine Biosciences Inc's solvency score is 90/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NBIX Price Targets Summary
Neurocrine Biosciences Inc
According to Wall Street analysts, the average 1-year price target for
NBIX
is 181.85 USD
with a low forecast of 148.47 USD and a high forecast of 213.15 USD.
Dividends
Current shareholder yield for
NBIX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
NBIX
stock under the Base Case scenario is
150.55
USD.
Compared to the current market price of 145.26 USD,
Neurocrine Biosciences Inc
is
Undervalued by 4%.